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Lymphangiogenesis, the formation of new lymphatic vessels, is associated to numerous pathologies1 and 
understanding the molecular and cellular basis of this complex process is essential for the development of novel 
therapeutic strategies. Studies on lymphangiogenesis have been hampered by difficulties in culturing lymphatic 
capillaries as three-dimensional (3D) structures in vitro that mimic the in vivo features of lymphatic vessels and 
lymphangiogenesis. 
The lymphatic ring assay described here phenocopies the different steps of lymphangiogenesis, including the 
spreading from a preexisting vessel, cell proliferation, migration and differentiation into capillaries. It consists on 
the adaptation of the aortic ring assay that has proved to be useful to investigate the molecular basis of 
angiogenesis2-4. The lymphatic ring model is an ideal assay for testing the activity of lymphangiogenic agonists 
or antagonists. The absence of inflammatory cells allows a simple interpretation of results and the determination 
of direct effects of compounds on lymphatic endothelial cell properties. Another advantage of the lymphatic ring 
assay is that cell outgrowing are primary cells which have not been modified by repeated passages or 
immortalization. This culture model bridges the gap between in vitro and in vivo studies and allows genetic 




• Mice CAUTION Mice (females or males) should be kept under specific pathogen-free conditions and used at 
6-16 weeks of age. All experiments should be done in accordance with protocols approved by the Local Ethical 
Committee. 
• Agarose type VII (Sigma-Aldrich, cat.no. A9045) 
• Norvanol D (VWR, cat.no. 90308-5000) CAUTION Flammable liquid. 
• Isoflo (Isofluran, Abbott) CAUTION Toxic, use in a chemical hood. 
• Phosphate Buffered Saline (PBS) (see REAGENT SETUP) 
• Evans Blue (MP Biomedicals, cat.no. 1.800.854.0530) 
• DMEM (GIBCO, cat.no. 10938-025) (see REAGENT SETUP) 
• Penicillin-streptomycin (GIBCO, cat.no. 2161) 
• Collagen R (2mg/ml) (Serva Electrophoresis, cat.no. 47254) 
• MEM 10X (GIBCO, cat.no. 042-90132M) 
• NaHCO3 (Sigma-Aldrich, cat.no. S-5761) (see REAGENT SETUP) 
• NaOH (Merck, cat.no. 1.06498) (see REAGENT SETUP) 
• MCDB 131 (GIBCO, cat.no.10372) (see REAGENT SETUP) 
• L-Gln (GIBCO, cat.no. 25030) 
• Ultroser G (Biosepra, cat.no. F126-01) 
• Heat-decomplemented Fetal Calf Serum (FCS, GIBCO, cat.no. 10106-169) 
• Ethanol 96% (VWR, cat.no. V905-320) 
•Paraformaldehyd (MERCK, cat.no. 1.04005.1000) CAUTION Toxic, avoid contact with skin, eyes and mucous 
membrane, use in a chemical hood. (see REAGENT SETUP) 
• HCl (MERCK, cat.no. 1.09057.1000) 
•Sodium Azide (NaN3, MERCK, cat.no. 1.06688.0100) CAUTION Toxic, avoid contact with skin, eyes and 
mucous membrane, use in a chemical hood. 
• Bovine Serum Albumin (BSA) (ACROS Organics, cat.no. 240401000) 
• Defatted Cow Powder Milk (Nestlé) 
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• Rabbit anti-LYVE-1 antibody (RELIATech, cat.no. 102-PA30S) 
• Swine anti-rabbit antibody (DAKO, cat.no. F 205) 
• Vectashield-propidium iodide mounting medium (Vector, cat.no. H1300) or -DAPI medium (Vector, cat.no. 
H1200) 
• Formaldehyd (Labonord, cat.no. 116 99031) (see REAGENT SETUP) 
• Whatman filter (Whatman, cat.no. 3017-915) 
• CaCO3 (Sigma-Aldrich, cat.no. C4830) 
• NaCl (VWR, cat.no. 27810.295) 
• Isopropanol (Labonord, cat.no. 116 99504) 
• Xylene (Labonord, cat.no. M6 99027) 
• Paraffin (Paraplast +, Labonord, cat.no. 069 48430) 
• Dimethylsulfoxid (DMSO) (MERCK, cat.no. 1.02931.1000) ! CAUTION Toxic, avoid contact with skin, eyes 
and mucous membrane, use in a chemical hood.  
Reagent setup
• Phosphate buffered saline (PBS) Add 17.52 g of NaCl, 7.34 g of K2HPO43H2O, 1.04 g of NaH2PO42H2O to 
a final volume of 2 litres H2O (double-distilled), filter on 0.22 µm. 
• Evans Blue (1.5%) Dissolve 1.5 g of Evans Blue into 100 ml of PBS. 
• Supplemented DMEM culture medium Add 1% penicillin-streptomycin; store this solution at 4 °C. 
• NaHCO3 (186 mM) Dissolve 156 mg in 10 ml H2O (double-distilled), filter on 0.22 µm; store this solution at 
4 °C. 
• NaHCO3 (1.1 M) Dissolve 924 mg in 10 ml H2O (double-distilled), filter on 0.22 µm; store this solution at 4 
°C. 
• NaOH (1M) Dissolve 2g pellets in 50 ml H2O (double-distilled), filter on 0.22 µm; store this solution at 4 °C. 
• Supplemented MCDB131 culture medium Add 1% penicillin-streptomycin, 1% L-Gln and 1% of NaHCO3 
(1.1 M); store this solution at 4 °C. 
• Paraformaldehyd (8%) Dissolve 4 g paraformadehyd in 50 ml H2O (double-distilled) and add 1 ml 1M NaOH. 
Stir at 65 °C until dissolved. Add 10 ml 10X PBS and allow cooling. Adjust pH to 7.4 using 1M HCl (need 
approximately 1 ml). Adjust final volume to 100 ml with H2O. Use immediately or aliquot at -20 °C. 
• Sodium azide/PBS (0.1%) Dissolve 1 g NaN3 in 1000 ml PBS); store this solution at 4 °C. 
• BSA (1.5%) /Powder Milk (3%)/PBS Dissolve 1.5 g BSA and 3 g unfatted powder milk in 100 ml PBS. Use 
immediately or aliquot at -20 °C 
• Neutral buffered formalin (4% formadehyd). Prepare a stock solution by dissolving 1kg CaCO3 into 5 litres of 
formaldehyd 35% and filter on Whatman filter paper 27 cm. From it, dilute 400 ml in 3.6 l H2O (double-
distilled) with 36 g NaCl. 
Equipment 
• Culture and bacterial dish: 10 cm tissue culture dish (Falcon, cat.no. 353003), 86×12 mm bacterial Petridish 
(Nunc, cat.no. 150340) 
• Dissecting board 
• Pins 
• Insulin syringe (Terumo, cat.no. U-100) 
• MiniCollect serum tubes (Greiner bio-one , cat.no. 450472) 
• Micro Centrifuge (Eppendorf 5415C) 
• Paper (Tork, cat.no. 120155) 
• Bell-jar 
• Scissors (World Precision Instruments, cat.no. 14393 and 15924) 
• Forceps (World Precision Instruments, cat.no. 15908) 
• Vannas scissors (World Precision Instruments, cat.no. 501839) 
• Microdissection forceps (World Precision Instruments, cat.no. 14099) 
• Surgical gauze pads, sterile (10×10 cm, Stella) 
• Binocular Microscope (Leica, Wild M650) 
• Ice 
• Punchers: 10 mm and 17 mm (VWR, cat.no. 5704401) 
• Handed-curved spatula (VWR, cat.no. 231.1026) 
• Millipore filter (0.22 µm, Millipore, cat.no. SLGP033RB) 
• Beaker (100 ml) 
• Magnetic stirrer and its power supply 
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• Vertical laminar flow work station Cleanair (Biohazard, VWR) 
• Surgical blade (Swann-Morton, cat.no. 0208) 
• Horizontal laminar flow workstation Cleanair (VWR) 
• Water-jacketed 5% CO2 and 5% O2 incubator (HERAcell 150, Heraeus) 
• Inverted phase contrast microscope (Zeiss, Axiovert 25) 
• Spoon (VWR, cat.no. 231-1252) 
• 24 well plate (Falcon, cat.no. 353047) 
• Orbital shaker (GFL 3006) 
• Microtome (Prosan, Microm HM310) 
• Microtome blade (Labonord, R35) 
• Superfrost Plus slides (Labonord, cat.no. 05305190) 
• 40 °C Plate (Medite OTS30) 




Material preparation TIMING 20 min 
1- Sterilize a beaker containing a magnetic stirrer. 
2- Heat the sterile stock agarose solution (1.5% type IV) in the microwave at full power (900 Watts) to liquefy 
and pour it in a 100 mm culture dish (25 ml/dish). Allow dish to gel at 4 °C for at least 3 hours. PAUSE POINT 
Gels can be left at 4 °C up to 2 weeks. 
3- For assay using transgenic mouse, collect autologous mouse serum. Pay attention to make this experiment in a 
minimum of time in order to prevent blood clotting. 
(A) Kill the mouse by cervical dislocation. 
(B) Lay the mouse back down on the dissecting board and fix forelegs upwards and hind legs downwards with 
pins. 
(C) Surface-sterilize the skin using Norvanol D or proprietary compounds. 
(D) Remove the skin and sternum to allow a direct access to heart. 
(E) Suck about 1 to 1.5 ml of blood with an insulin syringe inserted in the left ventricle of heart still beating. 
(F) Transfer blood in a MiniCollect serum tubes and centrifuge at 12,000g for 10 minutes. Keep supernatant at 4 
°C until use. TROUBLESHOOTING  
Mouse lymphatic thoracic duct dissection TIMING 1h for 3 mice 
4- Place an isofluran-soaked Tork paper in a bell-jar and keep it closed to saturate its atmosphere. Place a dish 
onto the paper to support the mouse in order to avoid direct contact with the isofluran. 
5- Sterilize instruments by immersing in Norvanol D or proprietary compounds. 
6- Kill the mouse by beheading after making animals unconscious in the saturated-Isofluran bell-jar. CRITICAL 
STEP Do not leave the mouse a long time in the Isofluran atmosphere, otherwise lymphatic cells would be fixed. 
7- Lay the mouse back down on the dissecting board and fix forelegs upwards and hind legs downwards with 
pins. 
8- Surface-sterilize the skin with Norvanol D or proprietary compounds. 
9- Cut the skin with sterile scissors and forceps along the abdominal midline and along the left and right anterior 
sides of the rib cage. Open the sternal plate and cut ribs, leaving the diaphragm intact. 
10- On the caudal side of the rib cage, cut the esophagus and the vena cava to remove all thoracic organs with 
sterile scissors and forceps (Fig. 1b). 
11- Fill rib cage with sterile PBS; wash out the blood with sterile gauze pads if needed. CRITICAL STEP Take 
care of maintaining the rib cage filled with liquid during the dissection. TROUBLESHOOTING 
12- Dissect carefully the periaortic fibroadipose tissue with very thin Norvanol-dry microdissection forceps 
under a binocular microscope (magnification 12X) (Fig. 1c). TROUBLESHOOTING 
13- Break carefully the fat beneath the lymphatic duct. It appears as a thin white transparent strand surrounded 
by fat. For training, it may be useful to identify the lymphatic thoracic duct by preliminary intradermal injection 
of Evans blue (1.5% PBS) into the paws and ears of donor mice 15 minutes before sacrifice (Fig. 1a). 
14- Remove the surrounding fat from the lymphatic duct (Fig. 1d). CRITICAL STEP Take care to clean the 
lymphatic dust as much as possible. TROUBLESHOOTING 
15- When the duct is clean from fat, cut its edges with Vannas scissors and immediately transfer it to a culture 
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dish containing penicillin/streptomycin supplemented ice-cold DMEM culture medium (Fig. 1e). Duct can be 
preserved for up to 3 hours at 4 °C during the preparation of collagen gels. 
Culture of mouse lymphatic thoracic duct rings TIMING 1 h - 1 h 30 
16- Punch agarose cylinders out of the previously prepared agarose gel with a 17-mm diameter puncher. Each 
agarose cylinder is then punch in its center with a 10-mm diameter puncher (24 agarose cylinders can be 
obtained from each 100 mm culture dish). Remove the inner agarose piece to get final cylinders. 
17- Transfer four of the agarose cylinders with a sterile spatula to an 86×12 bacterial Petri dish. 
18- Prepare the collagen solution on ice in a sterile beaker containing a magnetic stirrer by mixing 7.5 volumes 
of Collagen R (2 mg/ml) with 1 volume of 10x MEM, 1.5 volume of NaHCO3 (186 mM) and approximately 0.1 
volume of NaOH (1 M) to adjust the pH to 7.4 (according to modification of MEM color from yellow to purple). 
Keep mixing collagen mixture on ice during all experiment with a moderate magnetic stirrer rotation speed (100 
rpm). TROUBLESHOOTING 
19- Add 150µl of the collagen solution in each agarose cylinder. Allow it to polymerize 10-20 minutes at 37 °C. 
20- During collagen polymerisation, prepare the lymphatic thoracic duct pieces. Manipulator will choose 
between 2 procedures (option A and B). 
(A) First option 
In a vertical laminar airflow cabinet and with sterile microdissection forceps, transfer the lymphatic thoracic duct 
into an 86×12-mm Petri dish whose bottom is entirely recovered by 50% (vol/vol) DMEM/collagen mix. The 
collagen maintains the duct wet and DMEM avoids full adherence of the duct to collagen. Unfold the duct and 
cut it transversally with surgical blade into about 1mm-long pieces. According to the initial lymphatic thoracic 
duct length, it is possible to obtain 10 to 15 pieces from it. After cutting, immediately cover the pieces with 50% 
(vol/vol) DMEM/collagen mix and take care of maintaining pieces wet. CRITICAL STEP Do never allow the 
duct to dry. 
(B) Second option 
In a horizontal laminar airflow cabinet, with sterile microdissection forceps and Vannas scissor and under about 
12X magnification binocular microscope, cut the duct in the Petri dish filled with DMEM. By pulling duct with 
the forceps on one end, cut it with Vannas scissors on the other end. According to the initial lymphatic thoracic 
duct length, it is possible to cut 10 to 15 pieces from it (Fig. 1f). CRITICAL STEP Try to have pieces of the 
same length. 
21- With sterile microdissection forceps, transfer duct pieces to each previously polymerized collagen gels in 
agarose cylinder. CRITICAL STEP If manipulator choose option B in the step 20, first soak briefly duct pieces 
in a mix of 75% (vol/vol) DMEM/collagen before transferring pieces in the final collagen medium contained in 
the agarose cylinder. This step avoids the formation of a liquid layer surrounding the duct 
pieces.TROUBLESHOOTING 
22- Allow the duct pieces to fix to collagen in agarose cylinder by incubating dishes at 37 °C for 10 minutes. 
This step can be skipped. 
23- Cover the duct by adding 150µl of collagen solution. Allow it to polymerized 10 to 20 minutes at 37 °C. 
24- Add 6 ml of supplemented MCDB131 medium. To perform drug response assay, compounds diluted in PBS 
or DMSO (with a maximum of 0.1%) may be added once at the beginning of experiment to the culture. 
Depending of used drugs, choose one of the three following culture conditions: 
(A) For assay using stimulators of lymphangiogenesis: add 4% Ultroser G to culture medium. 
(B) For assay using inhibitors of lymphangiogenesis: add 10% FCS to culture medium. 
(C) For assay using transgenic mice: use 3% autologuous mouse serum isolated as explained at step 3. 
25- Maintain cultures at 37 °C in a humidified water-jacketed incubator under reduced oxygen conditions (5% 
O2, 5% CO2 and 90% N2) for 7 to 14 days. 
26- Observe rings with a phase contrast microscope after 7, 9 or 11 days of culture. 
Immunostaining of lymphatic rings 
26- Two methods for immunostaining are conceivable: whole mount fluorescence immunostaining (option A) or 
immunohistochemistry on paraffin-embedded sections (option B). Immunohistochemistry on frozen-sections is 
not possible because of the coarse-texture of collagen gel. 
(A) First option: Whole mount fluorescence immunostaining 
(i) At the end of the culture, harvest lymphatic rings with a little spoon from the agarose cylinder and transfer 
them in PBS for a wash of 1 hour. 
(ii) Fix washed lymphatic rings with 70% (vol/vol) ethanol/H2O or 4% paraformaldehyd for 30 minutes 
depending on the antibody to be tested. Disperse the rings in a 24-well plate filled with 70% (vol/vol) 
ethanol/H2O or in NaN3/PBS (0.1%) respectively. PAUSE POINT Rings can be kept for long period at 4°C. 
Look out for evaporation. 
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(iii) Wash the lymphatic rings to be used for immunostaining with PBS for 3 rounds of 20 minutes at 50 rpm on 
an orbital shaker. 
(iv) Block unspecific sites with 1.5% BSA-3% powder milk for 1 h at room temperature at 50 rpm on an orbital 
shaker. 
(v) Incubate the lymphatic rings with primary antibody diluted in 0.15% BSA/0.3% powder milk/PBS. Antibody 
suitable for cryosection staining can be used in our system provided an adaptation of the antibody dilution and 
incubation time (e.g. rabbit anti-LYVE-1 1/600 overnight at room temperature). To identify the putative 
unspecific labeling of the gel, a negative control (incubation of a lymphatic ring without the primary antibody 
but 0.15% BSA/0.3% Powder Milk/PBS) is required. 
(vi) Wash 4 times 15 minutes with PBS. 
(vii) Incubate lymphatic rings with the appropriate fluorochrome conjugated-secondary antibody as for the first 
antibody incubation (e.g. swine anti-rabbit-FITC 1/40, 1h30 at room temperature). 
(viii) Wash 4 times 15 minutes with P.B.S. 
(ix) Mount the lymphatic rings on a microscope slide with Vectashield-propidium iodide or-dapi mounting 
medium. TROUBLESHOOTING 
(B) Second option: Immunohistochemistry of paraffin-embedded lymphatic rings 
(i) Fix the lymphatic rings with 4% formaldehyd for 1 hour before transferring them in 70% (vol/vol) 
ethanol/H2O overnight. 
(ii) Transfer the specimens alternatively in a 95% (vol/vol) ethanol/H2O for 2 baths of 1 hour each, isopropanol 
for 2 baths of 1 hour each, xylene for 2 baths of 1 hour each and finally in paraffin overnight, for a first bath at 
56 °C and 1 hour for second bath at 56 °C. CRITICAL STEP Pay attention to locate the piece of lymphatic 
thoracic duct otherwise gel will not be visible anymore. 
(iii) Section paraffin blocks at 5µm on a microtome and let the slides dry on water drop on a Superfrost Plus 
slide layed on a 40 °C plate. 
(iv) Perform usual immunohistochemistry. CRITICAL STEP Tag the specimen location because it becomes 
invisible. 
TROUBLESHOOTING 
Step 3: Duct is broken during the sacrifice > During cervical dislocation for blood uptake, pay attention not to 
damage the vertebral spine otherwise the lymphatic duct will be broken as well. 
Step 3: Rings from transgenic mice which blood has been collected are less growing than other rings > It is 
preferable not to collect blood and duct on the same mouse; rings are usually less growing because the lymphatic 
duct may have dried. 
Steps 13-14: Lymphatic duct is broken during dissection > It won’t be detrimental for the culture process. 
Steps 11-21: No or only few rings are outgrowing > Totality or pieces of lymphatic duct dried. Pay attention to 
always keep them wet during dissection and preparation of collagen gels. 
Steps 12&21: No or only few rings are outgrowing > Whole or pieces of lymphatic duct fixed by alcohol. Pay 
attention to always dry Norvanol out of instruments before use. 
Steps 18-23: Collagen gel is fissured > It may be due to gelatine formation instead of collagen. Always let the 
soluble collagen on ice and take care to polymerize gels at neutral pH. 
Steps 18-23: Bubbles are present in collagen gel > Magnetic stirrer was going too fast. 
Step 21: Holes are present in collagen gel > Pay attention not to damage the collagen gel by introducing 
microsurgery forceps in it when adding the lymphatic duct piece. 
Steps 5-25: There is fungal or bacterial contamination > Always work with sterile instruments and under a flow 
work station while culturing. 
Step 26: Collagen gels are stained unspecifically > Test various concentrations of the secondary antibody and 
use the lowest working one. 
Step 26: Antibodies have precipitated in the collagen gel > Centrifuge primary and secondary antibodies before 
use and/or wash rings more intensively gels with PBS containing 1% Tween20.  
CRITICAL STEPS 





Published in : Nature Protocols (2008) 
Status : Postprint (Author’s version) 
ANTICIPATED RESULTS 
Lymphatic endothelial cell outgrowth 
In a typical experiment, lymphatic endothelial outgrowth is expected to take place within 5 to 7 days and to be 
maximal at day 11. The lymphangiogenic response is stimulated in a dose-dependent manner by serum and is 
never detected in its absence (Fig. 2a). Capillary formation is accelerated by lower pression of oxygen (5% O2). 
The percentage of outgrowing lymphatic rings should be in the range of 55 ± 6 % under ambient oxygen culture 
conditions and 87 ± 4.5 % when 5% O2 is employed. 
Immunostaining is carried out to confirm the lymphatic endothelial cell origin of outgrowing cells. The vascular 
network should be formed by LYVE-1 positive cells as assessed by two types of method available: whole mount 
or paraffin-embedded section immunostainings (Fig. 2a).  
Evaluation of lymphangiogenic agonists or antagonists 
In order to test putative lymphangiogenic factors, a chemically-defined serum (Ultroser) is used at a 
concentration of 4%. Indeed, the presence of at least VEGFs in FCS could interfere with the lymphangiogenic 
assay. Results from a typical experiment using VEGF-C as a well-recognized lymphangiogenic factor are shown 
in figure 3. Fibroblast Growth Factor (FGF) used as a negative control did not stimulate lymphangiogenesis in 
this assay. 
Screening for lymphangiogenic inhibitors can be evaluated in lymphatic ring cultures maintained in FCS-
supplemented medium. The addition of 10% FCS induces a much stronger lymphangiogenic response than the 
chemically defined serum (Ultroser) (Fig. 3). Fumagillin, which potently inhibits angiogenesis by blocking 
endothelial cell proliferation5 is also a potent inhibitor of cell spreading from lymphatic rings, when used at 2.5 
µg/ml concentration (Fig. 3). In sharp contrast, suramin, a polysulfonated naphthylurea that inhibits FGF6 is 
unable to block lymphatic outgrowth in 10% FCS-supplemented lymphatic ring cultures (Fig. 3). In order to 
check that the tested inhibitor does not exert any toxic effect, cell viability assays should be carried out at the end 
of the experiment according the manufacturer instructions (Viability/Cytotoxicity Kit, Molecular Probes). 
Genetic analysis 
A major potential application of the lymphatic ring model is the use of thoracic ducts derived from genetically 
modified mice to assess the role of candidate genes in lymphangiogenesis. Results from typical assays are shown 
in figure 3 in which the deletion of an individual matrix metalloproteinase (Mmp-2) impairs lymphatic 
endothelial cell outgrowth, while the deficiency of another one, Mmp-9, does not affect it. 
ACKNOWLEDGEMENTS 
We thank S. Itohara, C. Libert and Z. Werb for providing us with Mmp-deficient mice. We thank all members 
and collaborators of our laboratory who have contributed work or materials to the experiments, time and efforts 
toward establishing and optimizing this protocol. This work was supported by grants from the European Union 
Framework Program projects (FP6 and FP7), the Fonds National de la Recherche Scientifique (F.N.R.S., 
Belgium), the Fondation contre le Cancer, the Fonds spéciaux de la Recherche (University of Liège), the Centre 
Anticancéreux près l'Université de Liège, the D.G.T.R.E. from the « Région Wallonne » - NeoAngio 
programme, the Interuniversity Attraction Poles Program - Belgian Science Policy (Brussels, Belgium 
REFERENCES 
1. Karpanen,T. & Alitalo,K. Molecular Biology and Pathology of Lymphangiogenesis. Annu. Rev. Pathol. 
(2007). 
2. Nicosia,R.F. & Ottinetti,A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative 
assay of angiogenesis in vitro. Lab. Invest. 63, 115-122 (1990). 
3. Masson,V., V et al. Mouse Aortic Ring Assay: A New Approach of the Molecular Genetics of Angiogenesis. 
Biol. Proced. Online 4, 24-31 (2002). 
4. Devy,L. et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. 
FASEB J. 16, 147-154 (2002). 
5. Garrabrant,T. et al. Small molecule inhibitors of methionine aminopeptidase type 2 (MetAP-2). Angiogenesis 
7, 91-96 (2004). 
6. Kathir,K.M., Kumar,T.K. & Yu,C. Understanding the mechanism of the antimitogenic activity of suramin. 




Published in : Nature Protocols (2008) 
Status : Postprint (Author’s version) 
Figure 1 : Identification and visualization of lymphatic thoracic duct excision. 
For the setting up of the assay, thoracic duct is identified by intradermal injection of Evans blue (1.5% PBS) into 
the paws and ears of donor mice 15 minutes before sacrifice (a). For routine assays, Evans blue staining is not 
required and dissection is performed without staining. The lymphatic thoracic duct is dissected out of the mouse 
thoracic cavity filled with sterile PBS (b). Fat tissue above the aorta is first resected (c). Fat tissue surrounding 
the lymphatic thoracic duct is then carefully removed (d). Once the duct is completely separated from fat, both 
ends are cut with Vannas scissors and immediately transferred into an ice-cold DMEM-containing culture dish 
(e). Lymphatic thoracic duct is then cut into about 1mm long pieces and maintained in serum-free medium prior 
embedding into a collagen gel (f). Arrow heads delineate the lymphatic duct. Scale bars (a): 2 mm. (b): 5 mm, 
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Figure 2 : Lymphatic endothelial cell outgrowth.  
Lymphatic duct explants embedded in type I collagen gel are cultured for 9 days in medium supplemented with 
increasing concentrations of fetal calf serum (FCS, 0 to 20%), either under ambient or reduced oxygen 
conditions (21% O2 and 5% O2, respectively) (a). Immunostainings are performed on whole mount lymphatic 
ring after 9 days of culture using a anti-LYVE-1 antibody (in green) (b). A negative control using the secondary 
antibody reveals the unspecific staining of the lymphatic ring. Red staining corresponds to nuclear staining with 
propidium iodide. Immunohistochemistry is performed on lymphatic ring on parrafin-embedded section with the 
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Figure 3 : Modulation of lymphatic vessel outgrowth.  
To evaluate the pro-lymphangiogenic effect of growth factors, lymphatic rings are cultured in Ultroser-
supplemented medium; VEGF-C 10 ng/ml and FGF-2 10 ng/ml are added to cultures. For inhibition assays, 
control medium consists of standard medium containing 10% FCS; cultures are treated with 2.5 µg/ml 
Fumagillin (angiogenesis inhibitor) or 60 mg/ml Suramin (FGF trapper). Lymphatic rings derived from Mmp-2 
or Mmp-9-deficient mice (-/-) and the corresponding wild type mice (WT) are cultured in the presence of 
autologous mouse serum. Scale bars: 200 µm. 
 
  
 
